Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

• Published in: Clinical and translational science Vol. 10; no. 3; pp. 194 - 200
• Main Authors: Pai, AB, Meyer, DE, Bales, BC, Cotero, VE, Pai, MP, Zheng, N, Jiang, W
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2017; John Wiley and Sons Inc
• Subjects: Administration, Intravenous; Anemia; Animals; Assaying; Biological Assay - methods; Bleomycin; Calibration; Carbohydrates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deoxyribonucleic acid; DNA; FDA approval; Formulations; High performance liquid chromatography; Intravenous administration; Iron; Iron - metabolism; Iron Chelating Agents - pharmacology; Liquid chromatography; Manufacturing; Measurement methods; Methods; Oxidation-Reduction; Rats; Sodium; Sucrose; Sugar; United States > US
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.12443

Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron approved in the United States was sodium ferric gluconate complex in 2011. We evaluated chelatable and redox labile iron assay methods to measure the amount of labile iron released from i.v. iron formulations in biorelevant matrices in vitro. The majority of published labile iron assays evaluated were not suitable for use in vitro due to overwhelming interference by the presence of the i.v. iron products. However, an optimized high‐performance liquid chromatography (HPLC)‐based method performed well for use in vitro labile iron detection in a biorelevant matrix. Application of this method may enhance bioequivalence evaluation of generic i.v. iron formulations in the future.